A detailed history of Vanguard Group Inc transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,245,408 shares of TYRA stock, worth $19.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,245,408
Previous 1,238,501 0.56%
Holding current value
$19.2 Million
Previous $19.8 Million 47.85%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$16.7 - $24.36 $115,346 - $168,254
6,907 Added 0.56%
1,245,408 $29.3 Million
Q2 2024

Aug 13, 2024

BUY
$14.45 - $20.22 $4.89 Million - $6.85 Million
338,701 Added 37.64%
1,238,501 $19.8 Million
Q1 2024

May 10, 2024

BUY
$11.61 - $20.0 $1.64 Million - $2.82 Million
140,833 Added 18.56%
899,800 $14.8 Million
Q4 2023

Feb 14, 2024

BUY
$11.01 - $14.95 $290,476 - $394,425
26,383 Added 3.6%
758,967 $10.5 Million
Q3 2023

Nov 14, 2023

BUY
$13.15 - $16.08 $1.1 Million - $1.35 Million
83,709 Added 12.9%
732,584 $10.1 Million
Q2 2023

Aug 14, 2023

BUY
$11.99 - $17.51 $114,516 - $167,238
9,551 Added 1.49%
648,875 $11.1 Million
Q1 2023

May 15, 2023

BUY
$6.85 - $16.22 $239,455 - $567,002
34,957 Added 5.78%
639,324 $10.3 Million
Q4 2022

Feb 10, 2023

BUY
$5.68 - $8.81 $25,071 - $38,887
4,414 Added 0.74%
604,367 $4.59 Million
Q3 2022

Nov 14, 2022

BUY
$6.61 - $12.42 $58,458 - $109,842
8,844 Added 1.5%
599,953 $5.27 Million
Q2 2022

Aug 12, 2022

BUY
$5.26 - $11.19 $396,982 - $844,531
75,472 Added 14.64%
591,109 $4.23 Million
Q1 2022

May 13, 2022

SELL
$10.03 - $14.09 $8,485 - $11,920
-846 Reduced 0.16%
515,637 $5.52 Million
Q4 2021

Feb 14, 2022

BUY
$12.23 - $31.35 $6.32 Million - $16.2 Million
516,483 New
516,483 $7.27 Million

Others Institutions Holding TYRA

About Tyra Biosciences, Inc.


  • Ticker TYRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,973,600
  • Market Cap $646M
  • Description
  • Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...
More about TYRA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.